- Home
- AIBZ vs LXEO Comparison
AIBZ vs LXEO Comparison
Compare AIBZ & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Company Overview
Basic Information| Metric | AIBZ | LXEO |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.2M | 368.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | AIBZ | LXEO |
|---|---|---|
| Price | $7.07 | $5.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 684.0K | ★ 1.0M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.13 | $3.60 |
| 52 Week High | $9.91 | $10.99 |
Technical Indicators
Market Signals| Indicator | AIBZ | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 31.94 | 58.06 |
| Support Level | $6.13 | $5.01 |
| Resistance Level | $8.17 | $5.34 |
| Average True Range (ATR) | 1.06 | 0.33 |
| MACD | -0.19 | 0.06 |
| Stochastic Oscillator | 24.47 | 85.15 |
Price Performance
Historical Comparison AIBZ
LXEO
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.